Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
   Google Scholar
• Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015–2023.
   PubMed Web of Science ®Google Scholar
• Müller AMS, Ihorst G, Mertelsmann R, . Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1–12.
   PubMed Web of Science ®Google Scholar
• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;6:393–408.
   Google Scholar
• Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002;418:935–941.
   PubMed Web of Science ®Google Scholar
• Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell 2002;111:919–922.
   PubMed Web of Science ®Google Scholar
• Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 2004;5:407–441.
   PubMed Web of Science ®Google Scholar
• Griffin EA Jr, Staknis D, Weitz CJ. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science 1999; 286:768–771.
   PubMed Web of Science ®Google Scholar
• Kume K, Zylka MJ, Sriram S, . mCRY1 and mCRY2 are essential components of the negative limb of the circadianclock feedback loop. Cell 1999;98:193–205.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, . Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003;302: 255–259.
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, . The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41–50.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer 1997;70:241–247.
   PubMed Web of Science ®Google Scholar
• Gery S, Gombart AF, Yi WS, . Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 2005;106:2827–2836.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Leaderer D, Guss C, . Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007;120:432–435.
   PubMed Web of Science ®Google Scholar
• Lahti TA, Partonen T, Kyyrönen P, . Night-time work predisposes to non-Hodgkin lymphoma. Int J Cancer 2008;123:2148–2151.
   PubMed Web of Science ®Google Scholar
• Micke O, Schäfer U, Wörmann B, . Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls. Anticancer Res 1997;17:3007–3010.
   PubMed Web of Science ®Google Scholar
• Thoennissen NH, Iwanski GB, Doan NB, . Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009;69:5876–5884.
   PubMed Web of Science ®Google Scholar
• Iwanski GB, Lee DH, En-Gal S, . Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010;160:998–1007.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Kawamata N, . Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 2007;13:1399–1404.
   PubMed Web of Science ®Google Scholar
• Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107:600–608.
   PubMed Web of Science ®Google Scholar
• Botrugno OA, Santoro F, Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 2009;280:134–144.
   PubMed Web of Science ®Google Scholar
• Panda S, Antoch MP, Miller BH, . Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002;109: 307–320.
   PubMed Web of Science ®Google Scholar
• Kornmann B, Preitner N, Rifat D, . Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs. Nucleic Acids Res 2001;29:E51.
   PubMed Web of Science ®Google Scholar
• Mendez-Ferrer S, Lucas D, Battista M, . Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008;452: 442–447.
   PubMed Web of Science ®Google Scholar
• Chen ST, Choo KB, Hou MF, . Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005;26:1241–1246.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, . The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006;22:375–382.
   PubMed Web of Science ®Google Scholar
• Gery S, Virk R, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007;26:7916–7920.
   PubMed Web of Science ®Google Scholar
• Wood PA, Yang X, Hrushesky WJ. Clock genes and cancer. Integr Cancer Ther 2009;8:303–308.
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Ba Y, . The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 2008;6:1461–1468.
   PubMed Web of Science ®Google Scholar
• Yang MY, Chang JG, Lin PM, . Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 2006;97:1298–1307.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247–1250.
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Popplewell L, Nademanee A, . A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin's lymphoma: a California Cancer Consortium study. Haematologica 2009;94(Suppl. 2): Abstract 166.
   Google Scholar
• Wang H, Iakova P, Wilde M, . C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 2001;8:817–828.
   PubMed Web of Science ®Google Scholar
• Porse BT, Pedersen TA, Hasemann MS, . The proline-histidine-rich CDK2/CDK4 interaction region of C/EBPalpha is dispensable for C/EBPalpha-mediated growth regulation in vivo. Mol Cell Biol 2006;26:1028–1037.
   PubMed Web of Science ®Google Scholar
• Timchenko NA, Wilde M, Nakanishi M, . CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 1996;10:804–815.
   PubMed Web of Science ®Google Scholar
• Pedersen TA, Kowenz-Leutz E, Leutz A, . Cooperation between C/EBP alpha TBP/TFIIB and SWI/SNF recruiting domains is required for adipocyte differentiation. Genes Dev 2001;15:3208–3216.
   PubMed Web of Science ®Google Scholar
• Slomiany BA, D'Arigo KL, Kelly MM, . C/EBP alpha inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol Cell Biol 2000;20:5986–5997.
   PubMed Web of Science ®Google Scholar